In late November 2013, activist investor Carl Icahn disclosed a 12.5% stake in the company. Subsequently, the company adopted a poison pill to prevent a hostile takeover. In negotiations with the Company's board of directors, two additional directors backed by Mr. Icahn were added to the board, each managing directors of Icahn holding companies. Icahn considered his investment and intervention into Hologic to have been a success, with his nominees to the board of directors resigning on March 3, 2016 and exiting his position by May 16, 2016.